Deupsilocin clinical trials
Also written CYB003.
How each study uses deupsilocin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the deupsilocin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- CYB003
- 4
Studies by the year they started
4 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 1
Cybin IRL Limited (3) · Ohio State University (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test deupsilocin, phase 3 first.
- Jun 2027A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive DisorderPhase 3 · Cybin IRL Limited
Studies
Open first, then newest update. How each study uses deupsilocin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive DisorderRecruitingPhase 3Cybin IRL LimitedNCT06793397Written as CYB003
- A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and AnxietyRecruitingPhase 2Ohio State UniversityNCT06820723Written as CYB003
- Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)Enrolling by invitationPhase 3Cybin IRL LimitedNCT06605105Written as CYB003
- "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"CompletedPhase 3Cybin IRL LimitedNCT06564818Written as CYB003
Given beside what is tested · 1 — deupsilocin is usual care or a partner of the new treatment
Codes
What other systems call deupsilocin · ClinicalTrials.gg INT017109
- UNII (FDA) KXD3HS8D6XDEUPSILOCINOne source FDA
- NCI Thesaurus C203232DeupsilocinOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | KXD3HS8D6X | DEUPSILOCIN | One source FDA |
| NCI Thesaurus | C203232 | Deupsilocin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.